



**eLITERATURE
REVIEW**

eMedicalDermatology Review

Presented by
The Johns Hopkins University
School of Medicine, The Institute
for Johns Hopkins Nursing and the
University of Tennessee College
of Pharmacy

Supported by an Educational Grant
from Centacor, Inc.

POST-TEST & EVALUATION

June 2007 PODCAST Edition - ACPE Program #064-999-07-252-H01

Please Complete the Post-test and Evaluation and Mail/Fax to:

THE UNIVERSITY OF TENNESSEE

Health Science Center

College of Pharmacy

213 Conference Center

600 Henley Street

Knoxville, TN 37996

Tel: (865) 974-6605

Fax: (865) 974-2987

A statement of CE credit will be mailed within 4 weeks
of successful completion and evaluation of the program

Name _____

Address: _____

City: _____

State: _____ Zip: _____

Phone Number: _____

Post-test Question 1

Which ONE of the following medications has been used to treat patients with hepatitis C in conjunction with an antiviral regimen?

Answer Choices for Question 1

- A. infliximab
- B. efalizumab
- C. alefacept
- D. etanercept
- E. adalimumab

Question #1 Correct Answer & Commentary

- D. COMMENT: In a double-blind, placebo-controlled study, etanercept in combination with interferon and ribavirin resulted in absent hepatitis C virus RNA at 24 weeks in nearly 2/3 of patients compared to 1/3 of patients treated with placebo in combination with interferon and ribavirin.

Post-test Question 2

Which ONE of the following most accurately completes this statement: "Infliximab treatment should be withheld if liver function tests are increased by more than ____."

Answer Choices for Question 2

- A. the upper limit of normal
- B. two times the upper limit of normal
- C. three times the upper limit of normal
- D. four times the upper limit of normal
- E. five times the upper limit of normal

Question #2 Correct Answer & Commentary

- E. COMMENT: If liver function tests are increased more than five-fold, infliximab therapy should be withheld (RemicadeTM package insert).

Post-test Question 3

Which ONE of the following statements is TRUE about the association between TNF blockers and congestive heart failure?

Answer Choices for Question 3

- A. In a small clinical trial, infliximab 10 mg/kg was associated with a higher incidence of death or hospitalization than placebo-treated patients with congestive heart failure.
- B. In a small clinical trial, infliximab 5 mg/kg was not associated with an increase in death or hospitalization compared to placebo.
- C. Statistically significant increases in death or hospitalization have not been documented in clinical trials of etanercept or adalimumab.
- D. Hospitalizations for congestive heart failure were not increased in rheumatoid arthritis patients treated with TNF blockers compared with rheumatoid arthritis patients not treated with TNF blockers and to patients without rheumatoid arthritis.
- E. all of the above statements are TRUE.

Question #3 Correct Answer & Commentary

- E. COMMENT: In a Veterans Affairs study, 6.7% of rheumatoid arthritis patients treated with TNF blockers were hospitalized for congestive heart failure compared with 8% of control rheumatoid arthritis patients and 7% of non-rheumatoid arthritis control patients. Mortality rates were 3.8% for those treated with TNF blockers, 7% for controlled rheumatoid arthritis patients, and 11% for non-rheumatoid arthritis controls. Only infliximab at high dose (10mg/kg) has been associated with a higher incidence of death or hospitalization in one study.

Post-test Question 4

Which ONE of the following conditions can be exacerbated by TNF blockers?

Answer Choices for Question 4

- A. renal failure
- B. asthma
- C. multiple sclerosis
- D. Crohn's disease
- E. pyoderma gangrenosum

Question #4 Correct Answer & Commentary

- C. COMMENT: There are numerous reports of multiple sclerosis and demyelinating diseases brought on or exacerbated by treatment with TNF blockers.

Post-test Question 5

Which ONE of the following statements about autoantibody formation is NOT true?

Answer Choices for Question 5

- A. All of the currently available TNF blockers are associated with the formation of antinuclear antibodies.
- B. IgG anti-double-stranded DNA antibodies are formed more frequently in patients on TNF blockers than IgM anti-double-stranded DNA antibodies.
- C. IgG anti-double-stranded DNA antibodies pose a greater risk for the development of systemic lupus erythematosus than IgM antibodies.
- D. TNF blockers have been used successfully to treat forms of lupus.
- E. TNF blockers have been used successfully to treat forms of rheumatoid arthritis.

Question #5 Correct Answer & Commentary

- B. COMMENT: More patients develop IgM anti-double-stranded DNA antibodies than IgG antibodies on TNF blockers.

Post-test Question 6

The quantiferon gold test is indicated in which ONE of the following patients?

Answer Choices for Question 6

- A. A patient who was vaccinated with Bacillus of Calmette and Guérin (BCG) one year ago.
- B. A North American patient with a positive tuberculin skin test.
- C. A North American patient who immigrated from Korea 40 years ago and has a positive tuberculin skin test.
- D. A BCG-vaccinated patient who has a negative tuberculin skin test.
- E. A patient on long-term systemic steroids, who has a negative PPD.

Question #6 Correct Answer & Commentary

- A. COMMENT: The quantiferon gold assay tests for the presence of tuberculosis antigens excluding those antigens in BCG vaccinations.

EVALUATION

Evaluation Question 1

This program met my overall objectives.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 2

This program identifies which biologic agents are considered safe to use in patients with chronic infectious disease conditions such as Hepatitis C and tuberculosis.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 3

This program defines the appropriate use of biologics in patients with multiple sclerosis, lupus and/or malignancies.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree

	E. Strongly Disagree

Evaluation Question 4

This program details the appropriate use of biologics in patients with congestive heart failure.

	A. Strongly Agree
	B. Somewhat Agree
	C. Neutral
	D. Somewhat Disagree
	E. Strongly Disagree

Evaluation Question 5

What is your overall opinion of this program as it applies to your clinical practice?

	A. Very useful
	B. Somewhat useful
	C. Neutral
	D. Not very useful
	E. Not at all useful

Evaluation Question 6

In what way(s) can this program be improved?

Evaluation Question 7

CME activities must be "free of commercial bias for or against any product." In this regard, did you perceive any commercial influence in this web-based presentation?

	A. Yes (please explain)
--	-------------------------

<input type="checkbox"/>	B. No
--------------------------	-------

Evaluation Question 8

Did the author(s) disclose discussion of off-label drugs and/or devices?

<input type="checkbox"/>	A. Yes
--------------------------	--------

<input type="checkbox"/>	B. No (please explain)
--------------------------	------------------------

<input type="checkbox"/>	C. N/A - There was no discussion of off-label drugs and/or devices
--------------------------	--

Evaluation Question 9

Would you like to receive information on other CME activities?

<input type="checkbox"/>	A. Yes. My email address is:
--------------------------	------------------------------

<input type="checkbox"/>	B. No, thank you.
--------------------------	-------------------

Evaluation Question 10

Enter the number of hours it took you to complete this course (e.g., 0.5, 1.25, etc.):
